ALL1_OLEEU
ID ALL1_OLEEU Reviewed; 145 AA.
AC P19963; A5A5K8; A5A5K9; A5A5L0; A5A5L1; A5A5L2; A5A5L3; O24166; O24167;
AC O24168; Q41243; Q5DTB9; Q5DTC0; Q5DTC2; Q5DVQ3; Q5DVQ4; Q5DVQ5; Q5DVQ6;
AC Q5DVQ7; Q5DVQ9; Q5DVR0; Q5DVR4; Q5DVR6; Q5DVS1; Q5DVS3;
DT 01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-1993, sequence version 2.
DT 03-AUG-2022, entry version 99.
DE RecName: Full=Major pollen allergen Ole e 1;
DE AltName: Full=Allergen Ole e I;
DE AltName: Allergen=Ole e 1;
OS Olea europaea (Common olive).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC asterids; lamiids; Lamiales; Oleaceae; Oleeae; Olea.
OX NCBI_TaxID=4146;
RN [1]
RP PROTEIN SEQUENCE.
RC TISSUE=Pollen;
RX PubMed=8404906; DOI=10.1111/j.1432-1033.1993.tb18208.x;
RA Villalba M., Batanero E., Lopez-Otin C., Sanchez L.M., Monsalve R.I.,
RA Gonzalez de la Pena M.A., Lahoz C., Rodriguez R.;
RT "The amino acid sequence of Ole e I, the major allergen from olive tree
RT (Olea europaea) pollen.";
RL Eur. J. Biochem. 216:863-869(1993).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS OLE E I.2; OLE E I.3 AND OLE E
RP I.4.
RC TISSUE=Pollen;
RX PubMed=8195158; DOI=10.1016/s0021-9258(17)36594-8;
RA Villalba M., Batanero E., Monsalve R.I., Gonzalez de la Pena M.A.,
RA Lahoz C., Rodriguez R.;
RT "Cloning and expression of Ole e I, the major allergen from olive tree
RT pollen. Polymorphism analysis and tissue specificity.";
RL J. Biol. Chem. 269:15217-15222(1994).
RN [3]
RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS OLE E 1.0102; OLE E 1.0103 AND OLE
RP E 1.0105.
RC TISSUE=Pollen;
RX PubMed=9314349; DOI=10.1016/s0091-6749(97)70250-1;
RA Asturias J.A., Arilla M.C., Gomez-Bayon N., Martinez J., Martinez A.,
RA Palacios R.;
RT "Cloning and expression of the panallergen profilin and the major allergen
RT (Ole e 1) from olive tree pollen.";
RL J. Allergy Clin. Immunol. 100:365-372(1997).
RN [4]
RP PROTEIN SEQUENCE OF 1-28, AND VARIANTS.
RC TISSUE=Pollen;
RX PubMed=2241952; DOI=10.1016/0006-291x(90)90704-q;
RA Villalba M., Lopez-Otin C., Martin-Orozco E., Monsalve R.I., Palomino P.,
RA Lahoz C., Rodriguez R.;
RT "Isolation of three allergenic fractions of the major allergen from Olea
RT europea pollen and N-terminal amino acid sequence.";
RL Biochem. Biophys. Res. Commun. 172:523-528(1990).
RN [5]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 6-145, AND VARIANTS.
RC STRAIN=cv. Rowghani, and Zard;
RX PubMed=23454775;
RA Soleimani A., Morales S., Jimenez-Lopez J.C., Castro A.J.,
RA Rodriguez-Garcia M.I., de Dios Alche J.;
RT "Differential expression and sequence polymorphism of the olive pollen
RT allergen Ole e 1 in two Iranian cultivars.";
RL Iran. J. Allergy Asthma Immunol. 12:18-28(2013).
RN [6]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 14-145, AND VARIANTS.
RC STRAIN=cv. Acebuche, cv. Arbequina, cv. Bella de Espana, cv. Hojiblanca,
RC cv. Loaime, cv. Lucio, cv. Menara, cv. Picholine marocaine, and cv. Picual;
RX PubMed=18218146; DOI=10.1186/1471-2229-8-10;
RA Hamman-Khalifa A., Castro A.J., Jimenez-Lopez J.C., Rodriguez-Garcia M.I.,
RA Alche J.D.;
RT "Olive cultivar origin is a major cause of polymorphism for Ole e 1 pollen
RT allergen.";
RL BMC Plant Biol. 8:10-10(2008).
RN [7]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 16-145, AND GLYCOSYLATION.
RC TISSUE=Pollen;
RX PubMed=7982126; DOI=10.1111/j.1365-2222.1994.tb00988.x;
RA Lombardero M., Barbas J.A., del Prado J., Carreira J.;
RT "cDNA sequence analysis of the main olive allergen, Ole e I.";
RL Clin. Exp. Allergy 24:765-770(1994).
RN [8]
RP PARTIAL PROTEIN SEQUENCE, AND DISULFIDE BONDS.
RX PubMed=10667857; DOI=10.1034/j.1399-3011.2000.00138.x;
RA Gonzalez E., Monsalve R.I., Puente X.S., Villalba M., Rodriguez R.;
RT "Assignment of the disulfide bonds of Ole e 1, a major allergen of olive
RT tree pollen involved in fertilization.";
RL J. Pept. Res. 55:18-23(2000).
RN [9]
RP CHARACTERIZATION.
RX PubMed=9641567; DOI=10.1046/j.1365-2222.1998.00190.x;
RA Cardaba B., Del Pozo V., Jurado A., Gallardo S., Cortegano I., Arrieta I.,
RA Del Amo A., Tramon P., Florido F., Sastre J., Palomino P., Lahoz C.;
RT "Olive pollen allergy: searching for immunodominant T-cell epitopes on the
RT Ole e 1 molecule.";
RL Clin. Exp. Allergy 28:413-422(1998).
RN [10]
RP DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX PubMed=10393806; DOI=10.1242/jcs.112.15.2501;
RA Alche J.D., Castro A.J., Olmedilla A., Fernandez M.C., Rodriguez R.,
RA Villalba M., Rodriguez-Garcia M.I.;
RT "The major olive pollen allergen (Ole e I) shows both gametophytic and
RT sporophytic expression during anther development, and its synthesis and
RT storage takes place in the RER.";
RL J. Cell Sci. 112:2501-2509(1999).
RN [11]
RP GLYCAN STRUCTURE.
RX PubMed=10753962; DOI=10.1074/jbc.275.15.11451;
RA van Ree R., Cabanes-Macheteau M., Akkerdaas J., Milazzo J.-P.,
RA Loutelier-Bourhis C., Rayon C., Villalba M., Koppelman S., Aalberse R.,
RA Rodriguez R., Faye L., Lerouge P.;
RT "Beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong contribution
RT in IgE binding to plant glycoallergens.";
RL J. Biol. Chem. 275:11451-11458(2000).
RN [12]
RP DEVELOPMENTAL STAGE, AND SUBCELLULAR LOCATION.
RX PubMed=15509837; DOI=10.1093/pcp/pch127;
RA Alche J.D., M'rani-Alaoui M., Castro A.J., Rodriguez-Garcia M.I.;
RT "Ole e 1, the major allergen from olive (Olea europaea L.) pollen,
RT increases its expression and is released to the culture medium during in
RT vitro germination.";
RL Plant Cell Physiol. 45:1149-1157(2004).
RN [13]
RP MUTAGENESIS OF VAL-8; SER-9; GLN-10; PHE-11; PHE-26; GLU-29; LEU-30;
RP GLU-32; PHE-33; ILE-34; GLY-49; ASP-50; VAL-51; GLU-55; VAL-56; GLY-57;
RP TYR-58; THR-59; ARG-60; TYR-65; MET-67; GLU-70; LEU-107; ASN-108; THR-109;
RP VAL-110; GLY-112; PRO-119; LEU-120; PHE-123; LYS-125; GLN-133; VAL-134;
RP TYR-135; ASN-136; LYS-137; LEU-138; GLY-139; MET-140; TYR-141 AND PRO-142,
RP AND CHARACTERIZATION OF VARIANT ALA-28.
RX PubMed=15941589; DOI=10.1016/j.molimm.2005.04.015;
RA Gonzalez E.M., Villalba M., Quiralte J., Batanero E., Roncal F.,
RA Albar J.P., Rodriguez R.;
RT "Analysis of IgE and IgG B-cell immunodominant regions of Ole e 1, the main
RT allergen from olive pollen.";
RL Mol. Immunol. 43:570-578(2006).
RN [14]
RP MUTAGENESIS OF TYR-141; 136-ASN--MET-145 AND 141-TYR--MET-145, AND
RP ALLERGEN.
RX PubMed=17250698; DOI=10.1111/j.1365-2222.2006.02632.x;
RA Marazuela E.G., Rodriguez R., Barber D., Villalba M., Batanero E.;
RT "Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as
RT candidates for allergy vaccines.";
RL Clin. Exp. Allergy 37:251-260(2007).
RN [15]
RP GLYCOSYLATION, AND VARIANT ILE-106.
RC STRAIN=cv. Villacidro;
RX PubMed=18510354; DOI=10.1021/pr700855u;
RA Napoli A., Aiello D., Di Donna L., Moschidis P., Sindona G.;
RT "Vegetable proteomics: the detection of Ole e 1 isoallergens by peptide
RT matching of MALDI MS/MS spectra of underivatized and dansylated
RT glycopeptides.";
RL J. Proteome Res. 7:2723-2732(2008).
RN [16]
RP REVIEW, AND NOMENCLATURE.
RX PubMed=22385802; DOI=10.1016/j.talanta.2012.01.016;
RA Esteve C., Montealegre C., Marina M.L., Garcia M.C.;
RT "Analysis of olive allergens.";
RL Talanta 92:1-14(2012).
CC -!- FUNCTION: May be involved in recognition between pollen-stigma and
CC pollen tube-style cells.
CC -!- SUBCELLULAR LOCATION: Endoplasmic reticulum. Secreted.
CC -!- TISSUE SPECIFICITY: Expressed in tapetum and pollen grains. Not
CC detected in petals, roots or leaves. {ECO:0000269|PubMed:10393806}.
CC -!- DEVELOPMENTAL STAGE: Expressed at late stages of pollen development.
CC Up-regulated during pollen germination and pollen tube growth.
CC {ECO:0000269|PubMed:10393806, ECO:0000269|PubMed:15509837}.
CC -!- DOMAIN: Regions 91-102 and 109-130 are immunodominant T-cell epitopes.
CC Mutations in the C-terminus (135-145) reduce allergenic activity but do
CC not change the ability to stimulate allergen-specific T-cells.
CC -!- PTM: N-glycosylated; contains high mannose (Man(7)-GlcNAc) and
CC partially fucosylated complex glycans (GlcNAc-Man(3)-Xyl-GlcNAc).
CC Complex glycans may contribute to the antigenicity. Exists both in a
CC glycosylated and in a non-glycosylated form. Ole e 1 and Ole e 1.0103
CC are the only non-glycosylated isoallergens.
CC -!- PTM: A second potential glycosylation site exists at position 50 in cv.
CC Bella de Espana and cv. Hojiblanca.
CC -!- POLYMORPHISM: Several isoforms of the allergen exist due to
CC polymorphism.
CC -!- ALLERGEN: Causes an allergic reaction in human. Major allergen from
CC olive pollen. Important in Mediterranean countries.
CC {ECO:0000269|PubMed:17250698}.
CC -!- MISCELLANEOUS: Replacement of several other amino acids by Ala has
CC little or no effect on IgG binding.
CC -!- SIMILARITY: Belongs to the Ole e I family. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=CAA73036.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC Sequence=CAA73037.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC Sequence=CAA73038.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; Y12426; CAA73036.1; ALT_INIT; mRNA.
DR EMBL; Y12427; CAA73037.1; ALT_INIT; mRNA.
DR EMBL; Y12428; CAA73038.1; ALT_INIT; mRNA.
DR EMBL; AF500908; AAQ07442.1; -; mRNA.
DR EMBL; AF515277; AAQ08186.1; -; mRNA.
DR EMBL; AF515278; AAQ08187.1; -; mRNA.
DR EMBL; AF515279; AAQ08188.1; -; mRNA.
DR EMBL; AF515280; AAQ08189.1; -; mRNA.
DR EMBL; AF515281; AAQ08190.1; -; mRNA.
DR EMBL; AF532753; AAQ10267.1; -; mRNA.
DR EMBL; AF532754; AAQ10268.1; -; mRNA.
DR EMBL; AF532755; AAQ10269.1; -; mRNA.
DR EMBL; AF532756; AAQ10270.1; -; mRNA.
DR EMBL; AF532757; AAQ10271.1; -; mRNA.
DR EMBL; AF532758; AAQ10272.1; -; mRNA.
DR EMBL; AF532759; AAQ10273.1; -; mRNA.
DR EMBL; AF532760; AAQ10274.1; -; mRNA.
DR EMBL; AF532761; AAQ10275.1; -; mRNA.
DR EMBL; AF532762; AAQ10276.1; -; mRNA.
DR EMBL; AF532763; AAQ10277.1; -; mRNA.
DR EMBL; AF532764; AAQ10278.1; -; mRNA.
DR EMBL; AF532765; AAQ10279.1; -; mRNA.
DR EMBL; AF532766; AAQ10280.1; -; mRNA.
DR EMBL; AF532767; AAQ10281.1; -; mRNA.
DR EMBL; AY137467; AAN18042.1; -; mRNA.
DR EMBL; AY137468; AAN18043.1; -; mRNA.
DR EMBL; AY137469; AAN18044.1; -; mRNA.
DR EMBL; AY159880; AAO22132.1; -; Genomic_DNA.
DR EMBL; AY159881; AAO22133.1; -; Genomic_DNA.
DR EMBL; EF541386; ABP58632.1; -; mRNA.
DR EMBL; EF541387; ABP58633.1; -; mRNA.
DR EMBL; EF541388; ABP58634.1; -; mRNA.
DR EMBL; EF541389; ABP58635.1; -; mRNA.
DR EMBL; EF541390; ABP58636.1; -; mRNA.
DR EMBL; EF541391; ABP58637.1; -; mRNA.
DR EMBL; S75766; AAB32652.2; -; mRNA.
DR PIR; A36153; A36153.
DR PIR; A53806; A53806.
DR PIR; D53806; D53806.
DR PIR; S36872; S36872.
DR AlphaFoldDB; P19963; -.
DR SMR; P19963; -.
DR Allergome; 482; Ole e 1.
DR Allergome; 483; Ole e 1.0101.
DR Allergome; 487; Ole e 1.0105.
DR Allergome; 488; Ole e 1.0106.
DR Allergome; 489; Ole e 1.0107.
DR GlyConnect; 359; 10 N-Linked glycans (1 site).
DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR GO; GO:0005615; C:extracellular space; IEA:InterPro.
DR InterPro; IPR006040; Allergen_Ole_e_I_CS.
DR InterPro; IPR006041; Pollen_Ole_e1_allergen.
DR PANTHER; PTHR31614; PTHR31614; 1.
DR PROSITE; PS00925; OLEEI; 1.
PE 1: Evidence at protein level;
KW Allergen; Direct protein sequencing; Disulfide bond; Endoplasmic reticulum;
KW Glycoprotein; Secreted.
FT CHAIN 1..145
FT /note="Major pollen allergen Ole e 1"
FT /id="PRO_0000215113"
FT CARBOHYD 111
FT /note="N-linked (GlcNAc...) (complex) asparagine;
FT alternate"
FT CARBOHYD 111
FT /note="N-linked (GlcNAc...) (high mannose) asparagine;
FT alternate"
FT DISULFID 19..90
FT /evidence="ECO:0000269|PubMed:10667857"
FT DISULFID 22..131
FT /evidence="ECO:0000269|PubMed:10667857"
FT DISULFID 43..78
FT /evidence="ECO:0000269|PubMed:10667857"
FT VARIANT 3
FT /note="I -> V (in Ole e 1.0102, Ole e 1.0103 and Ole e
FT 1.0105)"
FT VARIANT 8
FT /note="V -> I (in Ole e I.4)"
FT VARIANT 12
FT /note="H -> Y (in Ole e I.4)"
FT VARIANT 13
FT /note="I -> V (in strain: cv. Zard; variant 2. In Ole e
FT I.4)"
FT VARIANT 14
FT /note="Q -> I (in strain: cv. Bella de Espana; variants 1
FT and 2, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2,
FT cv. Picholine marocaine and cv. Picual; variant 1)"
FT VARIANT 15
FT /note="G -> L (in strain: cv. Picual; variant 1)"
FT VARIANT 15
FT /note="G -> Q (in strain: cv. Arbequina; variants 1 and 2
FT and cv. Bella de Espana; variant 3)"
FT VARIANT 15
FT /note="G -> R (in strain: cv. Bella de Espana; variants 1
FT and 2, cv. Menara; variants 1 and 2 and cv. Picholine
FT marocaine)"
FT VARIANT 15
FT /note="G -> S (in strain: cv. Picual; variant 3)"
FT VARIANT 15
FT /note="G -> W (in strain: cv. Loaime and cv. Picual;
FT variant 2)"
FT VARIANT 16
FT /note="Q -> A (in strain: cv. Arbequina; variant 1)"
FT VARIANT 16
FT /note="Q -> D (in strain: cv. Arbequina; variant 2, cv.
FT Bella de Espana; variant 3 and cv. Picual; variant 3)"
FT VARIANT 16
FT /note="Q -> R (in strain: cv. Acebuche)"
FT VARIANT 16
FT /note="Q -> T (in strain: cv. Bella de Espana; variants 1
FT and 2, cv. Loaime, cv. Menara; variants 1 and 2, cv.
FT Picholine marocaine and cv. Picual; variants 1 and 2)"
FT VARIANT 17
FT /note="V -> I (in strain: cv. Rowghani; variant 3 and cv.
FT Zard; variant 2)"
FT VARIANT 17
FT /note="V -> S (in strain: cv. Arbequina; variant 2, cv.
FT Bella de Espana; variant 3, cv. Hojiblanca and cv. Picual;
FT variant 3)"
FT VARIANT 17
FT /note="V -> T (in strain: cv. Acebuche)"
FT VARIANT 18
FT /note="Y -> F (in strain: cv. Bella de Espana; variant 1)"
FT VARIANT 18
FT /note="Y -> H (in strain: cv. Menara; variant 2)"
FT VARIANT 18
FT /note="Y -> S (in strain: cv. Bella de Espana; variant 2
FT and cv. Picual; variant 2)"
FT VARIANT 18
FT /note="Y -> V (in strain: cv. Acebuche)"
FT VARIANT 19
FT /note="C -> Q (in strain: cv. Bella de Espana; variant 2)"
FT VARIANT 19
FT /note="C -> R (in strain: cv. Arbequina; variant 2 and cv.
FT Bella de Espana; variant 1)"
FT VARIANT 19
FT /note="C -> S (in strain: cv. Bella de Espana; variant 3)"
FT VARIANT 19
FT /note="C -> T (in strain: cv. Acebuche)"
FT VARIANT 20
FT /note="D -> G (in strain: cv. Acebuche and cv. Bella de
FT Espana; variant 3)"
FT VARIANT 20
FT /note="D -> V (in strain: cv. Bella de Espana; variant 1)"
FT VARIANT 21
FT /note="T -> H (in strain: cv. Bella de Espana; variant 3)"
FT VARIANT 21
FT /note="T -> Y (in strain: cv. Acebuche)"
FT VARIANT 23
FT /note="R -> C (in strain: cv. Bella de Espana; variant 2)"
FT VARIANT 23
FT /note="R -> P"
FT VARIANT 24
FT /note="A -> S (in strain: cv. Rowghani; variant 3. In Ole e
FT 1.0105)"
FT VARIANT 24
FT /note="A -> T (in Ole e I.4)"
FT VARIANT 25
FT /note="G -> R (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3 and cv. Rowghani; variants 3 and 4. In Ole e
FT 1.0105, Ole e I.3 and Ole e I.4)"
FT VARIANT 28
FT /note="T -> A (in strain: cv. Zard; variant 2; 50% loss of
FT IgG binding)"
FT /evidence="ECO:0000269|PubMed:15941589"
FT VARIANT 30
FT /note="L -> F (in Ole e I.4)"
FT VARIANT 35
FT /note="P -> L (in strain: cv. Zard; variant 2)"
FT VARIANT 38
FT /note="S -> G (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Hojiblanca and cv. Zard; variant 2. In Ole e
FT I.4)"
FT VARIANT 39
FT /note="L -> V (in strain: cv. Arbequina; variants 1 and 2,
FT cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca,
FT cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv.
FT Picholine marocaine, cv. Picual; variants 1 and 2, cv.
FT Rowghani; variants 2, 3 and 4 and cv. Zard; variants 1 and
FT 2. In Ole e 1.0102, Ole e 1.0103, Ole e 1.0105, Ole e I.3
FT and Ole e I.4)"
FT VARIANT 44
FT /note="K -> R (in strain: cv. Rowghani; variants 2, 3 and 4
FT and cv. Zard; variants 1 and 2. In Ole e 1.0105)"
FT VARIANT 45
FT /note="D -> E (in strain: cv. Zard; variant 1 and cv.
FT Rowghani; variants 2 and 3. In Ole e 1.0105)"
FT VARIANT 46
FT /note="K -> G (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Hojiblanca and cv. Rowghani; variant 4. In Ole
FT e I.3 and Ole e I.4)"
FT VARIANT 46
FT /note="K -> I"
FT VARIANT 46
FT /note="K -> R (in strain: cv. Arbequina; variants 1 and 2)"
FT VARIANT 46
FT /note="K -> S (in strain: cv. Zard; variant 2)"
FT VARIANT 47
FT /note="E -> K (in strain: cv. Rowghani; variant 2 and cv.
FT Zard; variants 1 and 2)"
FT VARIANT 48
FT /note="N -> K (in strain: cv. Zard; variant 2)"
FT VARIANT 50
FT /note="D -> K (in Ole e I.4)"
FT VARIANT 50
FT /note="D -> N (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Hojiblanca and cv. Zard; variant 2)"
FT VARIANT 50
FT /note="D -> S (in strain: cv. Rowghani; variant 4. In Ole e
FT I.3)"
FT VARIANT 51
FT /note="V -> I (in strain: cv. Arbequina; variants 1 and 2,
FT cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants
FT 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1
FT and 2, cv. Rowghani, variants 2, 3 and 4 and cv. Zard;
FT variants 1 and 2. In Ole e 1.0105, Ole e I.3 and Ole e
FT I.4)"
FT VARIANT 56
FT /note="V -> I (in strain: cv. Rowghani; variant 3. In Ole e
FT 1.0102, 1.0103 and 1.0105)"
FT VARIANT 58
FT /note="Y -> S (in strain: cv. Rowghani; variant 4)"
FT VARIANT 69
FT /note="V -> I (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2.
FT In Ole e I.3 and Ole e I.4)"
FT VARIANT 75
FT /note="N -> D (in strain: cv. Rowghani; variant 4. In Ole e
FT I.3)"
FT VARIANT 80
FT /note="I -> V (in strain: cv. Zard; variant 2)"
FT VARIANT 81
FT /note="T -> N (in strain: cv. Zard; variant 2)"
FT VARIANT 82
FT /note="L -> S (in strain: cv. Zard; variant 2)"
FT VARIANT 83
FT /note="I -> L (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3 and cv. Zard; variant 2. In Ole e I.4)"
FT VARIANT 86
FT /note="G -> S (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2.
FT In Ole e I.3 and Ole e I.4)"
FT VARIANT 87
FT /note="R -> S"
FT VARIANT 91
FT /note="N -> D (in strain: cv. Arbequina; variants 1 and 2,
FT cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca,
FT cv. Loaime, cv. Picual; variants 1 and 2, cv. Rowghani;
FT variants 3 and 4 and cv. Zard; variant 2. In Ole e 1.0105,
FT Ole e I.3 and Ole e I.4)"
FT VARIANT 95
FT /note="T -> I (in strain: cv. Rowghani; variant 3 and cv.
FT Zard; variant 2. In Ole e 1.0105)"
FT VARIANT 95
FT /note="T -> V (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3)"
FT VARIANT 99
FT /note="A -> V (in strain: cv. Acebuche, cv. Arbequina;
FT variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3,
FT cv. Hojiblanca, cv. Picual; variant 3, cv. Rowghani;
FT variants 1 and 4 and cv. Zard; variant 2. In Ole e I.2, Ole
FT e I.3 and Ole e I.4)"
FT VARIANT 100
FT /note="K -> R (in strain: cv. Zard; variant 2)"
FT VARIANT 103
FT /note="L -> V (in Ole e I.4)"
FT VARIANT 104
FT /note="K -> R (in strain: cv. Zard; variant 2)"
FT VARIANT 106
FT /note="K -> I (in strain: cv. Acebuche, cv. Arbequina;
FT variant 1 and 2, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv.
FT Menara; variants 1 and 2, cv. Picholine marocaine, cv.
FT Picual; variants 1, 2 and 3, cv. Rowghani; variants 1, 2
FT and 3 and cv. Zard; variant 1. In Ole e 1.0102, Ole e
FT 1.0103, Ole e 1.0105, Ole e I.2 and Ole e I.4)"
FT /evidence="ECO:0000269|PubMed:18510354"
FT VARIANT 106
FT /note="K -> L (in strain: cv. Zard; variant 2)"
FT VARIANT 106
FT /note="K -> M (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3)"
FT VARIANT 108
FT /note="N -> S (in Ole e 1.0103)"
FT VARIANT 111
FT /note="N -> D"
FT VARIANT 115
FT /note="R -> C (in strain: cv. Zard; variant 2)"
FT VARIANT 117
FT /note="V -> I (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Hojiblanca, cv. Rowghani; variant 2 and cv.
FT Zard; variants 1 and 2. In Ole e I.3 and Ole e I.4)"
FT VARIANT 118
FT /note="N -> K (in strain: cv. Zard; variant 2)"
FT VARIANT 121
FT /note="G -> R (in Ole e 1.0102)"
FT VARIANT 123
FT /note="F -> Y (in strain: cv. Zard; variant 1 and cv.
FT Rowghani; variant 2. In Ole e 1.0102 and Ole e 1.0103)"
FT VARIANT 125
FT /note="K -> N (in strain: cv. Zard; variant 2)"
FT VARIANT 126
FT /note="E -> K (in strain: cv. Zard; variant 2)"
FT VARIANT 132
FT /note="A -> P (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2.
FT In Ole e I.3 and Ole e I.4)"
FT VARIANT 135
FT /note="Y -> F (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2.
FT In Ole e I.3 and Ole e I.4)"
FT VARIANT 139
FT /note="G -> D (in strain: cv. Rowghani; variant 2)"
FT VARIANT 144
FT /note="N -> D (in strain: cv. Bella de Espana; variants 1,
FT 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2)"
FT VARIANT 144
FT /note="N -> T (in strain: cv. Picual; variant 3)"
FT VARIANT 145
FT /note="M -> HGMSR (in strain: cv. Acebuche)"
FT VARIANT 145
FT /note="M -> L (in strain: cv. Zard; variant 2)"
FT VARIANT 145
FT /note="M -> WNVTI (in strain: cv. Picual; variant 3)"
FT MUTAGEN 8
FT /note="V->A: 90% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 9
FT /note="S->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 10
FT /note="Q->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 11
FT /note="F->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 26
FT /note="F->A: 70% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 29
FT /note="E->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 30
FT /note="L->A: 50% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 32
FT /note="E->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 33
FT /note="F->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 34
FT /note="I->A: 50% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 49
FT /note="G->A: 50% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 50
FT /note="D->A: 60% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 51
FT /note="V->A: 50% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 55
FT /note="E->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 56
FT /note="V->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 57
FT /note="G->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 58
FT /note="Y->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 59
FT /note="T->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 60
FT /note="R->A: 60% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 65
FT /note="Y->A: 70% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 67
FT /note="M->A: 50% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 70
FT /note="E->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 107
FT /note="L->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 108
FT /note="N->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 109
FT /note="T->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 110
FT /note="V->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 112
FT /note="G->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 119
FT /note="P->A: 70% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 120
FT /note="L->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 123
FT /note="F->A: Loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 125
FT /note="K->A: 80% loss of IgG binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 133
FT /note="Q->A: 50% loss of IgG binding and 40% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 134
FT /note="V->A: 30% loss of IgG binding and 50% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 135
FT /note="Y->A: No loss of IgG binding and 40% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 136..145
FT /note="Missing: Decreased IgE binding."
FT /evidence="ECO:0000269|PubMed:17250698"
FT MUTAGEN 136
FT /note="N->A: 40% loss of IgG binding and 60% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 137
FT /note="K->A: 20% loss of IgG binding and 80% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 138
FT /note="L->A: 70% loss of IgG binding and 90% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 139
FT /note="G->A: 30% loss of IgG binding and 90% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 140
FT /note="M->A: 50% loss of IgG binding and 50% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
FT MUTAGEN 141..145
FT /note="Missing: Decreased IgE binding."
FT /evidence="ECO:0000269|PubMed:17250698"
FT MUTAGEN 141
FT /note="Y->A: 90% loss of IgG binding and 95% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589,
FT ECO:0000269|PubMed:17250698"
FT MUTAGEN 142
FT /note="P->A: 20% loss of IgG binding and 95% loss if IgE
FT binding."
FT /evidence="ECO:0000269|PubMed:15941589"
SQ SEQUENCE 145 AA; 16330 MW; 3F11F04E01C12C84 CRC64;
EDIPQPPVSQ FHIQGQVYCD TCRAGFITEL SEFIPGASLR LQCKDKENGD VTFTEVGYTR
AEGLYSMLVE RDHKNEFCEI TLISSGRKDC NEIPTEGWAK PSLKFKLNTV NGTTRTVNPL
GFFKKEALPK CAQVYNKLGM YPPNM
